aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize mental health treatment, Gilgamesh Pharmaceuticals is a clinical stage biotechnology company focused on developing innovative new chemical entities (NCEs). Leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience, and drug development expertise, the company aims to create rapid-acting and long-lasting therapies that target the root causes of neurological diseases. Their market focus is on precision psychiatric therapies that are orally bioavailable and move beyond symptom management.
Notable for its experienced team with a track record of successful biotech exits and inventions, Gilgamesh Pharmaceuticals has garnered attention from key investors in the biotech sector. The company has made significant strides in mental health science, utilizing an AI-powered discovery and translational platform to accelerate drug development. Their impact lies in the potential to offer safer, more effective treatments for mental health conditions, setting new standards in the industry.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Biotech
Technology
AI
Tags
Biotech
Model Types
Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Gilgamesh Pharmaceuticals founded?
Gilgamesh Pharmaceuticals was founded in 2019.
Where is Gilgamesh Pharmaceuticals's headquarters located?
Gilgamesh Pharmaceuticals's headquarters is located in New York City, NY, US.
When was Gilgamesh Pharmaceuticals's last funding round?
Gilgamesh Pharmaceuticals's most recent funding round was for $39M (USD) in December 2022.
How many employees does Gilgamesh Pharmaceuticals have?
Gilgamesh Pharmaceuticals has 22 employees as of Feb 5, 2024.
How much has Gilgamesh Pharmaceuticals raised to-date?
As of July 05, 2023, Gilgamesh Pharmaceuticals has raised a total of $68.6M (USD) since Dec 15, 2022.
Add Comparison
Total Raised to Date
$68.6M
USD
Last Update Dec 15, 2022
Last Deal Details
$39M
USD
Dec 15, 2022
Series B
Total Employees Over Time
22
As of Feb 2024
Gilgamesh Pharmaceuticals Address
113 University Pl
New York City,
New York
10003
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts